Selected outcomes in 2022

• Jirsova K, Levova K, Kalousova M, Fales I, Frankova V, Vesela V, Zima T, Utheim TP, Bednar J. Time and Temperature Stability of TGF-β1, EGF and IGF-1 in 20% and 100% Human Serum. Folia Biol (Praha). 2022;68(2):45-49. (IF2021: 1,167; Q3)
• Karasová M, Procházková J, Tylichová Z, Fedr R, Ciganek M, Machala M, Dvořák Z, Vyhlídalová B, Zůvalová I, Ehrmann J, Bouchal J, Andrysík Z, Vondráček J. Inhibition of Aryl Hydrocarbon Receptor (AhR) Expression Disrupts Cell Proliferation and Alters Energy Metabolism and Fatty Acid Synthesis in Colon Cancer Cells. Cancers (Basel). 2022 Aug 31;14(17):4245. doi: 10.3390/cancers14174245. (IF2021: 6.575; Q1)
• Mickova A, Morong M, Levková M, Kurfúrstová D, Kharaishvili G, Überall I, Student V Jr, Student V, Drapela S, Soucek K, Bouchal J. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer. Klin Onkol. 2022 Fall;35(6):473-481. English. doi: 10.48095/ccko2022473. (no IF; Q4)
• Ryska A. Complex pathological examination of non-small cell lung carcinoma – current status and challenges for the near future. Acta Medicinae 2022;11(3):114-117. (no IF) (in Czech).
• Ryska A. Predictive biomarkers in breast cancer – Current status and perspectives for the (near and distant) future. Acta Medicinae 2022;11(Speciál 2022):9-11. (no IF) (in Czech).
• Ryska A. The current standard of pathological examination of NSCLC in the Czech Republic. Onkologická revue 2022;9(3):210-212. (no IF) (in Czech).
• Seidler D, Karlíková M, Topolčan O, Snítilá M, Niedermair T, Brochhausen C. Establishing Biobanking in Medical Curricula-The Education Program "Precision Medicine International" (eduBRoTHER). Biopreserv Biobank. 2022 Nov 11. doi: 10.1089/bio.2022.0088.

Chosen results achieved by users of the LRI, bellow are selected 10 of them:

• de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Jóźwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. (IF2021: 50,739; Q1)
• Dundr P, Bártů M, Bosse T, Bui QH, Cibula D, Drozenová J, Fabian P, Fadare O, Hausnerová J, Hojný J, Hájková N, Jakša R, Laco J, Lax SF, Matěj R, Méhes G, Michálková R, Šafanda A, Němejcová K, Singh N, Stolnicu S, Švajdler M, Zima T, Stružinská I, McCluggage WG. Primary mucinous tumors of the ovary: an interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories. Mod Pathol 2022, doi.org/10.1016/j.modpat.2022.100040, (IF2021: 8,209; Q1)
• Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T, Sochorova K, Rozkova D, Sojka L, Dundr P, Laco J, Brtnicky T, Praznovec I, Halaska MJ, Rob L, Ryska A, Coosemans A, Vergote I, Cibula D, Bartunkova J, Galon J, Galluzzi L, Spisek R. An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clin Cancer Res. 2022 Jul 15;28(14):3053-3065. doi: 10.1158/1078-0432.CCR-21-4413. (IF2021: 13,801; Q1)
• Hensler M, Rakova J, Kasikova L, Lanickova T, Pasulka J, Holicek P, Hraska M, Hrnciarova T, Kadlecova P, Schoenenberger A, Sochorova K, Rozkova D, Sojka L, Drozenova J, Laco J, Horvath R, Podrazil M, Hongyan G, Brtnicky T, Halaska MJ, Rob L, Ryska A, Coosemans A, Vergote I, Garg AD, Cibula D, Bartunkova J, Spisek R, Fucikova J. Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. Oncoimmunology. 2022 Jul 22;11(1):2101596. doi: 10.1080/2162402X.2022.2101596. (IF2021:7,723; Q1)
• Obermannova R, Selingerova I, Rehak Z, Jedlicka V, Slavik M, Fabian P, Novotny I, Zemanova M, Studentova H, Grell P, Zdrazilova Dubska L, Demlova R, Harustiak T, Hejnova R, Kiss I, Vyzula R. PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study. Ther Adv Med Oncol. 2022 Jan 5;13:17588359211065153. doi: 10.1177/17588359211065153. (IF2021: 8,168; Q1)
• Reischig T, Kacer M, Vlas T, Drenko P, Kielberger L, Machova J, Topolcan O, Kucera R, Kormunda S. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. Am J Transplant. 2022 Mar;22(3):801-812. doi: 10.1111/ajt.16902. (IF2021: 9,369; Q1)
• Soukup J, Manethova M, Faistova H, Krbal L, Vitovcova B, Hornychova H, Drugda J, Cesak T, Netuka D, Gabalec F, Ryska A. Pitx2 is a useful marker of midgut-derived neuroendocrine tumours - an immunohistochemical study of 224 cases. Histopathology. 2022 Dec;81(6):799-807. doi: 10.1111/his.14789. (IF2021: 7,778; Q1)
• Štorkánová H, Oreská S, Špiritović M, Heřmánková B, Bubová K, Kryštůfková O, Mann H, Komarc M, Slabý K, Pavelka K, Šenolt L, Zámečník J, Vencovský J, Tomčík M.Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. Front Immunol. 2022 Jan 28;13:811045. doi: 10.3389/fimmu.2022.811045. (IF2021: 8,787; Q1)
• Wolrab D, Jirásko R, Cífková E, Höring M, Mei D, Chocholoušková M, Peterka O, Idkowiak J, Hrnčiarová T, Kuchař L, Ahrends R, Brumarová R, Friedecký D, Vivo-Truyols G, Škrha P, Škrha J, Kučera R, Melichar B, Liebisch G, Burkhardt R, Wenk MR, Cazenave-Gassiot A, Karásek P, Novotný I, Greplová K, Hrstka R, Holčapek M. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022 Jan 10;13(1):124. doi: 10.1038/s41467-021-27765-9. (IF2021: 17,694; Q4)
• Zhang Y, Vagiannis D, Budagaga Y, Sabet Z, Hanke I, Rozkoš T, Hofman J. Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. Pharmaceutics. 2022 Nov 24;14(12):2595. doi: 10.3390/pharmaceutics14122595. (IF2021: 6,525; Q1)